Algenomics, a company specializing in the development of ribonucleic acid (RNA)-based gene therapies, announced on June 15 that the interim results of its RNA editing and correction-based anticancer gene therapy, 'RZ-001 (Taspitimagen advec),' for recurrent glioblastoma (rGBM) were presented at the Asian Society of Neuro-Oncology (ASNO 2026) held in Kanazawa, Japan, on June 13.


Professor Jaeyong Kim of the Department of Neurosurgery at Seoul National University Bundang Hospital presented the interim results of the Phase 1/2a clinical trial of the company's RNA editing and correction-based anticancer gene therapy 'RZ-001 (Taspitimagen advec)' for recurrent glioblastoma (rGBM) at the Asian Society for Neuro-Oncology (ASNO 2026) held in Kanazawa, Japan on the 13th. Algenomics

Professor Jaeyong Kim of the Department of Neurosurgery at Seoul National University Bundang Hospital presented the interim results of the Phase 1/2a clinical trial of the company's RNA editing and correction-based anticancer gene therapy 'RZ-001 (Taspitimagen advec)' for recurrent glioblastoma (rGBM) at the Asian Society for Neuro-Oncology (ASNO 2026) held in Kanazawa, Japan on the 13th. Algenomics

View original image

This presentation was conducted by Professor Jaeyong Kim of the Department of Neurosurgery at Seoul National University Bundang Hospital, who introduced the safety and early efficacy results from the ongoing clinical trial. RZ-001 is an anticancer gene therapy utilizing Algenomics' RNA replacement enzyme platform, designed to selectively express therapeutic genes in tumor cells to eliminate cancer cells.


According to the presentation, a total of 20 patients have completed screening to date, with 10 of them enrolled in the clinical trial and receiving treatment. In the interim analysis, no new safety concerns related to the treatment have been identified so far. No dose limiting toxicity (DLT) has been reported, and no Grade 4 or higher adverse events related to the treatment have been observed. Most adverse events were assessed as disease-related reactions commonly observed in glioblastoma patient populations or associated with underlying conditions.


In addition, some patients demonstrated long-term tumor recurrence suppression and disease control lasting more than six months. Recurrent glioblastoma is a representative intractable brain tumor with a high recurrence rate and extremely poor prognosis, even after standard treatment. The effectiveness of currently approved treatment options remains limited, and immuno-oncology drugs have also failed in clinical trials, making this a field with an urgent unmet medical need for new therapeutic mechanisms.


Professor Jaeyong Kim stated, "The data obtained so far indicate the manageable safety of RZ-001 as well as early results suggesting clinical activity. In particular, since many cases of recurrent glioblastoma relapse within two to four months, data from patients who have shown long-term recurrence suppression—especially those with suppression lasting more than nine months—are very noteworthy."



He added, "We expect that additional patient enrollment and long-term follow-up will allow us to confirm the clinical value more clearly." Meanwhile, RZ-001 is currently under clinical development for both recurrent glioblastoma and hepatocellular carcinoma (HCC), and the HCC program received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA in May this year.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing